Forbes·2025-12-01 14:50Core Viewpoint - The pharmaceutical companies Eli Lilly and Novo Nordisk are reducing the prices of their weight loss drugs to enhance accessibility for consumers [1]. Pricing Changes - Eli Lilly has decreased the out-of-pocket monthly price for the lowest single-dose vial of Zepbound to $299 from $349, marking a 14% reduction. The 5-milligram dose is now priced at $399, down approximately 20% from $499. Prices for the 7.5 to 15 milligram doses have been reduced to $449 from $499 [2]. - Novo Nordisk has announced a reduction in the out-of-pocket monthly price for Ozempic and Wegovy to $349 from $499. Additionally, the two lowest doses of either drug will be available for $199 per month for the first two months [3]. Market Reaction - Following the announcement of price cuts, Eli Lilly's shares fell nearly 1% in premarket trading, while Novo Nordisk's stock experienced a decline of more than 1.7% [3].